Based on the acquired knowledge on the molecular biology of this disease [4], new approaches (i.e. combination therapy where chemotherapeutic agents are administered with compounds, such as inhibitors, targeting pro-survival proteins and protein kinases) in pancreatic cancer treatment have recently emerged [5]. This evidence concerns the gene WEE1 and pancreatic neoplasm.